In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model

Abstract excerpt

BACKGROUND: Plasma concentration of low-density lipoprotein (LDL) cholesterol is a well-established risk factor for cardiovascular disease. Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9), which regulates cholesterol homeostasis, has recently emerged as an approach to reduce cholesterol levels. The development of humanized animal models is an important step to validate and study human drug...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cholesterol and Lipid Metabolism
• Share to Lipoproteins and Cardiovascular Health
• Share to Receptor Mechanisms and Signaling